Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
168.5 USD +1.71% Intraday chart for Zoetis Inc. -1.45% -14.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zoetis Inc Receives a Shareholder Proposal from John Chevedden CI
EU Regulator Initiates Antitrust Probe on US Animal Health Company Zoetis MT
European Commission Opens Antitrust Probe Into Zoetis MT
EU Opens Antitrust Investigation Into Zoetis MT
Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules -- 2nd Update DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules -- Update DJ
EU to Investigate Zoetis Over Possible Breach of Competition Rules DJ
EU targets Zoetis in antitrust investigation over dog medicines RE
Old demons return as tech takes a dive Our Logo
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys... Our Logo
Transcript : Zoetis Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM
Transcript : Zoetis Inc. Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 11:40 AM
Phew! The party continues! Our Logo
ANALYST RECOMMENDATIONS : Datadog, Doordash, Nvidia, Trimble, Walmart... Our Logo
Piper Sandler Raises Price Target on Zoetis to $220 From $215, Maintains Overweight Rating MT
Zoetis Insider Sold Shares Worth $603,957, According to a Recent SEC Filing MT
Barclays Adjusts Price Target on Zoetis to $260 From $255, Maintains Overweight Rating MT
Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics CI
Health Care Limits Losses Amid Defensive Bias -- Health Care Roundup DJ
Global markets live: TUI, Coca-Cola, Biogen, ARM Holdings, Glencore... Our Logo
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Sector Update: Health Care MT
Pet products maker Zoetis sees annual profit below estimates on weak demand RE
Transcript : Zoetis Inc., Q4 2023 Earnings Call, Feb 13, 2024
Zoetis' Q4 Earnings, Revenue Advance; Fiscal 2024 Outlook Issued; Shares Drop Pre-Bell MT
Chart Zoetis Inc.
More charts
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
168.5 USD
Average target price
221.9 USD
Spread / Average Target
+31.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Zoetis Inc. - Nyse
  4. News Zoetis Inc.
  5. Earnings Flash (ZTS) ZOETIS Posts Q3 EPS $1.25